Details

Autor(en) / Beteiligte

• Cavalcanti, Alexandre B
• Zampieri, Fernando G
• Rosa, Regis G
• Azevedo, Luciano C.P
• Veiga, Viviane C
• Avezum, Alvaro
• Damiani, Lucas P
• Marcadenti, Aline
• Kawano-Dourado, Letícia
• Lisboa, Thiago
• Junqueira, Debora L. M
• de Barros e Silva, Pedro G.M
• Tramujas, Lucas
• Abreu-Silva, Erlon O
• Laranjeira, Ligia N
• Soares, Aline T
• Echenique, Leandro S
• Pereira, Adriano J
• Freitas, Flávio G.R
• Gebara, Otávio C.E
• Dantas, Vicente C.S
• Furtado, Remo H.M
• Milan, Eveline P
• Golin, Nicole A
• Cardoso, Fábio F
• Maia, Israel S
• Hoffmann Filho, Conrado R
• Kormann, Adrian P.M
• Amazonas, Roberto B
• Bocchi de Oliveira, Monalisa F
• Serpa-Neto, Ary
• Falavigna, Maicon
• Lopes, Renato D
• Machado, Flávia R
• Berwanger, Otavio

Titel

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Ist Teil von

• The New England journal of medicine, 2020-11, Vol.383 (21), p.2041-2052

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Patients with confirmed or suspected Covid-19 were randomly assigned to receive hydroxychloroquine with azithromycin, hydroxychloroquine alone, or usual care. The primary outcome was clinical status at 15 days, assessed on a seven-level ordinal scale. There were no significant differences between groups in the primary outcome.